Claims for Patent: 10,864,199

Summary for Patent: 10,864,199

Title:	Tacrolimus for improved treatment of transplant patients
Abstract:	An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.
Inventor(s):	Gordon; Robert D. (Sandy Springs, GA), Holm; Per (Vanlose, DK), Lademann; Anne-Marie (Klampenborg, DK), Norling; Tomas (Lyngby, DK)
Assignee:	VELOXIS PHARMACEUTICALS A/S (Kobenhavn, DK)
Application Number:	15/041,986
Patent Claims:	1. A method of suppressing kidney rejection in a kidney transplant patient comprising orally administering once daily in the evening to the kidney transplant patient an extended release pharmaceutical composition comprising tacrolimus, wherein (i) the in vivo release of the extended release pharmaceutical composition after oral administration takes place substantially in the colon, (ii) the extended release pharmaceutical composition further comprises a modifying release agent, (iii) the pharmaceutical composition provides a substantially zero order release profile, and (iv) at least 8% w/w of the tacrolimus in the composition is released within 4 hours, 40% w/w of the tacrolimus is released within 10 to 14 hours, and less than 62% w/w of the tacrolimus in the composition is released within 15 hours, when subjected to an in vitro dissolution test using the USP II Paddle method at a rotation speed of 50 ppm in a 900 mL aqueous dissolution medium at pH 4.5 with 0.005% hydroxypropylcellulose. 2. The method of claim 1, wherein the in vivo release of the extended release pharmaceutical composition after oral administration takes place substantially in one or more of the colon ascendens, colon transversum and colon descendens. 3. The method of claim 1, wherein the oral administration of the composition results in a plasma concentration of about 5 ng/mL to about 20 ng/mL for at least about 24 hours. 4. The method of claim 1, wherein the pharmaceutical composition is administered once daily for at least 7 days. 5. The method of claim 1, wherein the pharmaceutical composition administered comprises from 0.1 to 15 mg of tacrolimus. 6. The method of claim 1, wherein the pharmaceutical composition administered comprises from 0.5 to 5 mg of tacrolimus. 7. The method of claim 1, wherein the pharmaceutical composition administered comprises 1 mg of tacrolimus. 8. The method of claim 1, wherein the pharmaceutical composition is orally administered without simultaneous food intake. 9. The method of claim 1, wherein the patient is a de novo kidney transplant patient. 10. The method of claim 1, wherein the pharmaceutical composition further comprises a hydrophilic or water-miscible vehicle, and the tacrolimus in the pharmaceutical composition is present in the vehicle. 11. The method of claim 10, wherein the vehicle is selected from a polyethylene glycol, a polyoxyethylene oxide, poloxamer, polyoxyethylene stearate, poly-epsilon caprolactone, polyglycolized glycerides, polyvinylpyrrolidone, polyvinyl-polyvinylacetate copolymer, polyvinyl alcohol, polymethacrylic polymer hydroxypropyl methylcellulose, hydroxypropyl cellulose, methylcellulose, sodium carboxymethylcellulose, hydroxyethyl cellulose, a pectin, a cyclodextrin, galactomannan, alginate, carragenate, xanthan gum, and mixtures thereof. 12. The method of claim 10, wherein the vehicle comprises poloxamer. 13. The method of claim 10, wherein the vehicle comprises a mixture of polyethylene glycol and poloxamer. 14. A method of suppressing kidney rejection in a kidney transplant patient comprising orally administering once daily to the kidney transplant patient an extended release pharmaceutical composition comprising tacrolimus without restriction as to the time of day of administration, wherein (i) the pharmaceutical composition was prescribed without restriction as to the time of day of administration, (ii) the in vivo release of the extended release pharmaceutical composition after oral administration takes place substantially in the colon, (iii) the extended release pharmaceutical composition further comprises a modifying release agent, (iv) the pharmaceutical composition provides a substantially zero order release profile, and (v) at least 8% w/w of the tacrolimus in the composition is released within 4 hours, 40% w/w of the tacrolimus is released within 10 to 14 hours, and less than 62% w/w of the tacrolimus in the composition is released within 15 hours, when subjected to an in vitro dissolution test using the USP II Paddle method at a rotation speed of 50 ppm in a 900 mL aqueous dissolution medium at pH 4.5 with 0.005% hydroxypropylcellulose. 15. The method of claim 9, wherein the treatment is initiated at a starting daily dose of 0.14 mg/kg of tacroliumus. 16. The method of claim 14, wherein the patient is a de novo kidney transplant patient and the treatment is initiated at a starting daily dose of 0.14 mg/kg of tacroliumus. 17. A method of suppressing kidney rejection in a kidney transplant patient being treated with an immediate release oral tacrolimus product, the method comprising: (a) discontinuing treatment of the kidney transplant patient with the immediate release oral tacrolimus pharmaceutical composition; and (b) initiating once daily oral administration to the kidney transplant patient in the evening of an extended release pharmaceutical composition comprising tacrolimus, wherein (I) the in vivo release of the extended release pharmaceutical composition after oral administration takes place substantially in the colon, (II) the ratio of (i) tacrolimus previously administered daily with the immediate release pharmaceutical composition to (ii) tacrolimus initially administered daily with the extended release pharmaceutical composition is 1:0.66-0.80, (III) the extended release pharmaceutical composition further comprises a modifying release agent, (IV) the pharmaceutical composition provides a substantially zero order release profile, and (V) at least 8% w/w of the tacrolimus in the composition is released within 4 hours, 40% w/w of the tacrolimus is released within 10 to 14 hours, and less than 62% w/w of the tacrolimus in the composition is released within 15 hours, when subjected to an in vitro dissolution test using the USP II Paddle method at a rotation speed of 50 ppm in a 900 mL aqueous dissolution medium at pH 4.5 with 0.005% hydroxypropylcellulose. 18. The method of claim 17, wherein the ratio of (i) tacrolimus administered daily with the immediate release pharmaceutical composition to (ii) tacrolimus initially administered daily with the extended release pharmaceutical composition is 1:0.80. 19. The method of claim 17, wherein the extended release pharmaceutical composition is orally administered without simultaneous food intake.